Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.
David BauchéSmita MauzeChristina KochelJeff GreinAnandi SawantYulia ZybinaWendy BlumenscheinPeng YangLakshmanan AnnamalaiJennifer H YearleyJuha PunnonenEdward P BowmanAlissa ChackerianDrake LafacePublished in: Journal for immunotherapy of cancer (2021)
These data suggest that using CTLA4 antagonists with no Fc-effector function can mitigate gut inflammation associated with anti-CTLA4 antibody therapy yet retain potent antitumor activity in combination with PD-1 blockade.